IDiyas

For the Inventor, By the Inventor

Parsippany, NJ, United States of America

Paul Allen Sutton

USPTO Granted Patents = 18 


 

Average Co-Inventor Count = 4.9

ph-index = 7

Forward Citations = 107(Granted Patents)


Location History:

  • Parsippany, NJ (US) (2007 - 2016)
  • Getsville, NY (US) (2021)
  • Getzville, NY (US) (2023)

Company Filing History:

goldMedal15 out of 3,923 
 
Novartis Ag
 patents
silverMedal3 out of 19 
 
Novartis Pharmaceuticals Corporation
 patents
bronzeMedal2 out of 8 
 
Novartis Pharma Gmbh
 patents
where one patent can have more than one assignee

Years Active: 2007-2023

where 'Filed Patents' based on already Granted Patents

18 patents (USPTO):
1. 11786498 - Sacubitril calcium salts (2023-10-17),
2. 11642329 - Amorphous solid form of compounds containing S—N-valeryl-N- {[2'-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations (2023-05-09),
3. 11096918 - Amorphous solid form of compounds containing S—N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations (2021-08-24),
4. 9388134 - Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations (2016-07-12),
5. 9334276 - Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor (2016-05-10),
6. 9163005 - Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2015-10-20),
7. 8877938 - Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations (2014-11-04),
8. 8865897 - [object Object] (2014-10-21),
9. 8829194 - Crystalline forms of the sodium salt of (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid (2014-09-09),
10. 8829015 - Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2014-09-09),
11. 8580806 - Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2013-11-12),
12. 8501785 - Salts of benzimidazolyl pyridyl ethers and formulations thereof (2013-08-06),
13. 8415363 - Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2013-04-09),
14. 8389537 - Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2013-03-05),
15. 8343984 - Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2013-01-01),

Title: Paul Allen Sutton: A Brilliant Innovator in the Pharmaceutical Industry

Introduction:

In the world of pharmaceutical innovations, Paul Allen Sutton of Parsippany, NJ, stands out as a prominent name. With an impressive 18 patents to his credit, Sutton has made significant contributions to the field. This article examines his latest patents, career highlights, collaborations, and acknowledges his invaluable contributions to the industry.

Latest Patents:

Among Sutton's recent patents, two deserve special mention. The first is the invention of sacubitril calcium salts. These polymorphic forms of the calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester have proven useful in treating various conditions and disorders responsive to the inhibition of neutral endopeptidases.

The second patent relates to an amorphous solid form of compounds containing S-N-valeryl-N- {[2'-(1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations. This compound is a combination of the angiotensin receptor antagonist valsartan, the neutral endopeptidase inhibitor (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester, and sodium cations. It holds significant potential for treating hypertension and heart failure.

Career Highlights:

Paul Allen Sutton's career in the pharmaceutical industry showcases his dedication and expertise. Notably, he has worked with esteemed companies like Novartis AG and Novartis Pharmaceuticals Corporation. His contributions have had a substantial impact on the development of groundbreaking drugs and medical treatments.

Collaborations:

Sutton has enjoyed collaborations with esteemed professionals in his field. Noteworthy among his coworkers are Piotr Henryk Karpinski and Paul William Manley. These collaborations have enhanced Sutton's ability to deliver cutting-edge solutions to the healthcare industry and have opened up new avenues of research and development.

Conclusion:

Paul Allen Sutton's inventive spirit and expertise in the pharmaceutical field have made him a distinguished innovator. With 18 patents to his name, including his latest inventions, Sutton has contributed significantly to advancements in medical treatments. His collaborations and tenure at prestigious companies such as Novartis AG and Novartis Pharmaceuticals Corporation further validate his status as a respected figure in the industry. As Sutton continues to explore new horizons, we anticipate further remarkable contributions to pharmaceutical innovations and the betterment of healthcare worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…